Despite successful percutaneous coronary intervention (PCI), many patients with STEMI still go on to develop heart failure. And microvascular obstruction is strongly associated with hospitalisation and mortality within one year. SSO₂ Therapy has been shown to reduce endothelial swelling and restore microvascular flow, leading to reductions in infarct size.1, 2

Lower patient risks and minimise myocardial damage

Harness the power of SSO₂ Therapy to decrease the risks of heart failure and hospitalisation in your patients. The TherOx SSO₂ Therapy closed-loop system is simple to set up and easy to use. The one-time 60-minute infusion of superoxygenated blood minimises myocardial damage and lowers the risk of future complications.

HELPFUL RESOURCES

Understand the SSO2 Therapy dual mechanism of action

SSO₂ Therapy provides an infusion of superoxygenated blood with a pO₂ level of 1,000 mmHg, which is about seven to 10 times higher than normal arterial blood. The therapy can reverse capillary oedema, nurturing heart tissue with oxygenated blood.

Learn More

Reduce infarct size

Studies show that SSO₂ Therapy creates a 26% relative infarct size reduction and improvement of left ventricular function in LAD STEMI.1

Lower the risk of heart failure and mortality

SSO₂ Therapy has been associated with a lower one-year rate of all-cause mortality or new-onset heart failure.2, 3

Learn More

1 Acute Myocardial Infarction With Hyperoxemic Therapy (AMIHOT), Journal: Journal of the American College of Cardiology, : 2007, ISSN: 0735-1097

2 https://doi.org/10.1016/j.jcin/2023.08.001

3 https://doi.org/10.1002/ccd.29090